

# Lorenz C Hofbauer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6554808/lorenz-c-hofbauer-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

338  
papers

19,748  
citations

65  
h-index

131  
g-index

393  
ext. papers

22,645  
ext. citations

7.4  
avg, IF

6.85  
L-index

#	Paper	IF	Citations
338	Bone fragility in diabetes: novel concepts and clinical implications.. <i>Lancet Diabetes and Endocrinology</i> , <b>2022</b> ,	18.1	6
337	Effects of vitamin D, omega-3 fatty acids and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial.. <i>American Journal of Clinical Nutrition</i> , <b>2022</b> ,	7	1
336	Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2022</b> , 60, 109-117	5.9	0
335	Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes.. <i>Frontiers in Endocrinology</i> , <b>2022</b> , 13, 835720	5.7	1
334	Bone cell-specific deletion of thyroid hormone transporter Mct8 distinctly regulates bone volume in young versus adult male mice.. <i>Bone</i> , <b>2022</b> , 159, 116375	4.7	0
333	The mevalonate pathway in breast cancer biology. <i>Cancer Letters</i> , <b>2022</b> , 542, 215761	9.9	1
332	High stroma-derived WNT5A is an indicator for low-risk prostate cancer. <i>FEBS Open Bio</i> , <b>2021</b> , 11, 1186-1194	11.9	1
331	Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 147, 2233-2238	4.9	5
330	Novel approaches to target the microenvironment of bone metastasis. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 488-505	19.4	16
329	From Pharmacology to Physiology: Endocrine Functions of Opioid Receptor Networks. <i>Trends in Endocrinology and Metabolism</i> , <b>2021</b> , 32, 306-319	8.8	4
328	Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. <i>Bone Research</i> , <b>2021</b> , 9, 24	13.3	2
327	Late-onset hypogonadism: Clinical evidence, biological aspects and evolutionary considerations. <i>Ageing Research Reviews</i> , <b>2021</b> , 67, 101301	12	1
326	Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells. <i>Leukemia</i> , <b>2021</b> , 35, 2936-2947	10.7	0
325	Skeletal endocrinology: where evolutionary advantage meets disease. <i>Bone Research</i> , <b>2021</b> , 9, 28	13.3	2
324	The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
323	Osteoporose bei Diabetes mellitus. <i>Diabetes Aktuell</i> , <b>2021</b> , 19, 178-183	0	
322	Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases. <i>Journal of Bone and Mineral Research</i> , <b>2021</b> , 36, 1906-1913	6.3	1

321	Rodent Models of Spondyloarthritis Have Decreased White and Bone Marrow Adipose Tissue Depots. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 665208	8.4	1
320	New insights into the role of glycosaminoglycans in the endosteal bone microenvironment. <i>Biological Chemistry</i> , <b>2021</b> , 402, 1415-1425	4.5	3
319	Shaping the bone through iron and iron-related proteins. <i>Seminars in Hematology</i> , <b>2021</b> , 58, 188-200	4	3
318	Interactions of Anemia, FGF-23, and Bone in Healthy Adults-Results From the Study of Health in Pomerania (SHIP). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e288-e299	5.6	5
317	Emerging Players in Prostate Cancer-Bone Niche Communication. <i>Trends in Cancer</i> , <b>2021</b> , 7, 112-121	12.5	11
316	Role of osteogenic Dickkopf-1 in bone remodeling and bone healing in mice with type I diabetes mellitus. <i>Scientific Reports</i> , <b>2021</b> , 11, 1920	4.9	2
315	Mice lacking DKK1 in T cells exhibit high bone mass and are protected from estrogen-deficiency-induced bone loss. <i>IScience</i> , <b>2021</b> , 24, 102224	6.1	6
314	Systemic PPAR $\alpha$ Antagonism Reduces Metastatic Tumor Progression in Adipocyte-Rich Bone in Excess Weight Male Rodents. <i>Journal of Bone and Mineral Research</i> , <b>2021</b> ,	6.3	1
313	Epo/EpoR signaling in osteoprogenitor cells is essential for bone homeostasis and Epo-induced bone loss. <i>Bone Research</i> , <b>2021</b> , 9, 42	13.3	3
312	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1855-1868	27.4	62
311	Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice. <i>Bone</i> , <b>2020</b> , 137, 115400	4.7	3
310	Disruption of BMP Signaling Prevents Hyperthyroidism-Induced Bone Loss in Male Mice. <i>Journal of Bone and Mineral Research</i> , <b>2020</b> , 35, 2058-2069	6.3	4
309	Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	6
308	Leopard skin. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 456	18.1	
307	Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. <i>Bone</i> , <b>2020</b> , 134, 115268	4.7	25
306	High serum levels of periostin are associated with a poor survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 180, 515-524	4.4	6
305	Thyroid Hormone Actions and Bone Remodeling - The Role of the Wnt Signaling Pathway. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2020</b> , 128, 450-454	2.3	10
304	Evolving functions of Dickkopf-1 in cancer and immunity. <i>Cancer Letters</i> , <b>2020</b> , 482, 1-7	9.9	10

303	Contributions of Dickkopf-1 to Obesity-Induced Bone Loss and Marrow Adiposity. <i>JBMR Plus</i> , <b>2020</b> , 4, e10364	3.9	4
302	Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	6
301	Bone Metabolism in Cancer <b>2020</b> , 503-511		1
300	Skeletal health in patients following allogeneic hematopoietic cell transplantation. <i>Bone</i> , <b>2020</b> , 115684	4.7	1
299	Dorsomorphin: A novel inhibitor of Dickkopf-1 in breast cancer. <i>Biochemical and Biophysical Research Communications</i> , <b>2020</b> , 524, 360-365	3.4	2
298	Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2619-2627	7.5	10
297	Lack of the Thyroid Hormone Transporter Mct8 in Osteoblast and Osteoclast Progenitors Increases Trabecular Bone in Male Mice. <i>Thyroid</i> , <b>2020</b> , 30, 329-342	6.2	2
296	Pharmacological mechanisms of therapeutics: Receptor activator of nuclear factor- $\kappa$ B ligand inhibition <b>2020</b> , 1689-1710		1
295	Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	5
294	Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2020</b> , 1873, 188351	11.2	39
293	Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2020</b> , 204, 105734	5.1	10
292	The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective. <i>Frontiers in Cell and Developmental Biology</i> , <b>2020</b> , 8, 586031	5.7	5
291	Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> ,	5.6	43
290	Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. <i>Cell Death and Disease</i> , <b>2019</b> , 10, 91	9.8	38
289	The Role of Dickkopf-1 in Thyroid Hormone-Induced Changes of Bone Remodeling in Male Mice. <i>Endocrinology</i> , <b>2019</b> , 160, 664-674	4.8	6
288	Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes. <i>Annals of Hematology</i> , <b>2019</b> , 98, 2063-2072	3	6
287	Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. <i>Endocrine Connections</i> , <b>2019</b> , 8, R55-R70	3.5	34
286	Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. <i>Endocrine Connections</i> , <b>2019</b> , 8, 923-934	3.5	10

285	Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation. <i>Oncogene</i> , <b>2019</b> , 38, 4773-4787	9.2	3
284	Osteogenic Dkk1 Mediates Glucocorticoid-Induced but Not Arthritis-Induced Bone Loss. <i>Journal of Bone and Mineral Research</i> , <b>2019</b> , 34, 1314-1323	6.3	21
283	Increased pore size of scaffolds improves coating efficiency with sulfated hyaluronan and mineralization capacity of osteoblasts. <i>Biomaterials Research</i> , <b>2019</b> , 23, 26	16.8	16
282	Loss of Dkk-1 in Osteocytes Mitigates Alveolar Bone Loss in Mice With Periodontitis. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2924	8.4	10
281	Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1369-1378	12.9	17
280	Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signaling. <i>Nature Metabolism</i> , <b>2019</b> , 1, 111-124	14.6	36
279	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. <i>Bone</i> , <b>2019</b> , 120, 44-49	4.7	13
278	Denosumab: a new treatment option for glucocorticoid-induced osteoporosis. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 428-429	18.1	4
277	Immunoabsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report. <i>Diabetes Care</i> , <b>2018</b> , 41, e23-e24	14.6	10
276	Bone health during endocrine therapy for cancer. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 901-910	18.1	54
275	Differential effects of high-fat diet and exercise training on bone and energy metabolism. <i>Bone</i> , <b>2018</b> , 116, 120-134	4.7	24
274	Postnatal Skeletal Deletion of Dickkopf-1 Increases Bone Formation and Bone Volume in Male and Female Mice, Despite Increased Sclerostin Expression. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 1698-1707	6.3	26
273	Selective inhibition of receptor activator of NF- $\kappa$ B ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction. <i>Journal of Molecular Medicine</i> , <b>2018</b> , 96, 559-573	5.5	2
272	Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data. <i>Leukemia Research</i> , <b>2018</b> , 69, 81-86	2.7	3
271	Thy-1 (CD90) promotes bone formation and protects against obesity. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	51
270	Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo. <i>Scientific Reports</i> , <b>2018</b> , 8, 8711	4.9	19
269	Role of WNT5A receptors FZD5 and RYK in prostate cancer cells. <i>Oncotarget</i> , <b>2018</b> , 9, 27293-27304	3.3	17
268	Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway. <i>Haematologica</i> , <b>2018</b> , 103, 61-68	6.6	12

267	Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption. <i>Frontiers in Cell and Developmental Biology</i> , <b>2018</b> , 6, 127	5.7	8
266	Myelodysplastic syndromes and bone loss in mice and men. <i>Leukemia</i> , <b>2017</b> , 31, 1003-1007	10.7	13
265	Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 164, 737-743	4.4	5
264	Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. <i>Breast Cancer Research</i> , <b>2017</b> , 19, 92	8.3	17
263	Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism. <i>Endocrinology</i> , <b>2017</b> , 158, 3765-3777	4.8	10
262	Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 2288-2296	6.3	6
261	Immune Suppressive and Bone Inhibitory Effects of Prednisolone in Growing and Regenerating Zebrafish Tissues. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 2476-2488	6.3	34
260	Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells. <i>Scientific Reports</i> , <b>2017</b> , 7, 6460	4.9	91
259	Osteoporosis treatment: recent developments and ongoing challenges. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 898-907	18.1	315
258	Site-Specific Variations in Bone Mineral Density under Systemic Conditions Inducing Osteoporosis in Minipigs. <i>Frontiers in Physiology</i> , <b>2017</b> , 8, 426	4.6	3
257	Bone defect regeneration and cortical bone parameters of type 2 diabetic rats are improved by insulin therapy. <i>Bone</i> , <b>2016</b> , 82, 108-15	4.7	34
256	GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. <i>Osteoporosis International</i> , <b>2016</b> , 27, 2967-78	5.3	31
255	Effects of insulin therapy on porosity, non-enzymatic glycation and mechanical competence in the bone of rats with type 2 diabetes mellitus. <i>Bone</i> , <b>2016</b> , 91, 186-93	4.7	5
254	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1532-1543	59.2	725
253	Antibodies for the Treatment of Bone Diseases: Clinical Data <b>2016</b> , 239-255		
252	Bone Formation and the Wnt Signaling Pathway. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1902-1903	59.2	13
251	Postmenopausal osteoporosis. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16069	51.1	263
250	Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes. <i>Diabetes</i> , <b>2016</b> , 65, 1757-66	0.9	93

249	Effects of parathyroid hormone on cortical porosity, non-enzymatic glycation and bone tissue mechanics in rats with type 2 diabetes mellitus. <i>Bone</i> , <b>2016</b> , 82, 116-21	4.7	12
248	Thyrotropin serum levels are differentially associated with biochemical markers of bone turnover and stiffness in women and men: results from the SHIP cohorts. <i>Osteoporosis International</i> , <b>2016</b> , 27, 719-27	5.3	10
247	p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. <i>Cell Death and Disease</i> , <b>2016</b> , 7, e2119	9.8	32
246	Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells. <i>Cancer Letters</i> , <b>2016</b> , 375, 162-171	9.9	23
245	Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 2323-32	3.3	6
244	Role of milk fat globule-epidermal growth factor 8 in osteoimmunology. <i>BoneKey Reports</i> , <b>2016</b> , 5, 820		2
243	Basics of Bone Biology <b>2016</b> , 1-30		
242	The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155087	3.7	11
241	Microdialysis Sampling from Wound Fluids Enables Quantitative Assessment of Cytokines, Proteins, and Metabolites Reveals Bone Defect-Specific Molecular Profiles. <i>PLoS ONE</i> , <b>2016</b> , 11, e0159580	3.7	12
240	Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1877-1887	6.3	46
239	Functional Interference in the Bone Marrow Microenvironment by Disseminated Breast Cancer Cells. <i>Stem Cells</i> , <b>2016</b> , 34, 2224-35	5.8	13
238	Milk Fat Globule-Epidermal Growth Factor 8 (MFG-E8) Is a Novel Anti-inflammatory Factor in Rheumatoid Arthritis in Mice and Humans. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 596-605	6.3	27
237	Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors. <i>Haematologica</i> , <b>2016</b> , 101, 1499-1507	6.6	35
236	Sulfated hyaluronan improves bone regeneration of diabetic rats by binding sclerostin and enhancing osteoblast function. <i>Biomaterials</i> , <b>2016</b> , 96, 11-23	15.6	43
235	Sclerostin Blockade-A Dual Mode of Action After All?. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1787-1790	6.3	5
234	WNT5A and Its Receptors in the Bone-Cancer Dialogue. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1488-96	6.3	11
233	Structural and functional insights into sclerostin-glycosaminoglycan interactions in bone. <i>Biomaterials</i> , <b>2015</b> , 67, 335-45	15.6	33
232	Serum Fetuin-A levels and abdominal aortic calcification in healthy men - The STRAMBO study. <i>Bone</i> , <b>2015</b> , 79, 196-202	4.7	13



231	More DATA to guide sequential osteoporosis therapy. <i>Lancet, The</i> , <b>2015</b> , 386, 1116-8	4.0	11
230	Loss of milk fat globule-epidermal growth factor 8 (MFG-E8) in mice leads to low bone mass and accelerates ovariectomy-associated bone loss by increasing osteoclastogenesis. <i>Bone</i> , <b>2015</b> , 76, 107-14	4.7	13
229	Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1. <i>Endocrinology</i> , <b>2015</b> , 156, 3517-27	4.8	37
228	Effects of adolescence-onset hypogonadism on metabolism, bone mineral density and quality of life in adulthood. <i>Journal of Pediatric Endocrinology and Metabolism</i> , <b>2015</b> , 28, 1047-55	1.6	6
227	P38 regulates the Wnt inhibitor Dickkopf-1 in breast cancer. <i>Biochemical and Biophysical Research Communications</i> , <b>2015</b> , 466, 728-32	3.4	7
226	Bioinspired Collagen/Glycosaminoglycan-Based Cellular Microenvironments for Tuning Osteoclastogenesis. <i>ACS Applied Materials &amp; Interfaces</i> , <b>2015</b> , 7, 23787-97	9.5	36
225	Associations between ambient air pollution and bone turnover markers in 10-year old children: results from the GINIplus and LISAPLUS studies. <i>International Journal of Hygiene and Environmental Health</i> , <b>2015</b> , 218, 58-65	6.9	17
224	Myelodysplasia is in the niche: novel concepts and emerging therapies. <i>Leukemia</i> , <b>2015</b> , 29, 259-68	10.7	56
223	Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 44-54	7.5	31
222	Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children. <i>Scientific Reports</i> , <b>2015</b> , 5, 18138	4.9	26
221	From Bone Cell Biology to Novel Therapies of Osteoporosis. <i>Drug Research</i> , <b>2015</b> , 65 Suppl 1, S14-5	1.8	2
220	WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 471-80	6.3	32
219	Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 154, 623-31	4.4	12
218	Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. <i>International Journal of Endocrinology</i> , <b>2015</b> , 2015, 838202	2.7	25
217	Cancer-targeted therapies and radiopharmaceuticals. <i>BoneKEy Reports</i> , <b>2015</b> , 4, 707		1
216	Loss of bone strength in HLA-B27 transgenic rats is characterized by a high bone turnover and is mainly osteoclast-driven. <i>Bone</i> , <b>2015</b> , 75, 183-91	4.7	7
215	Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats. <i>PLoS ONE</i> , <b>2015</b> , 10, e0131192	3.7	27
214	Oncologic resection achieving r0 margins improves disease-free survival in parathyroid cancer. <i>Annals of Surgical Oncology</i> , <b>2014</b> , 21, 1891-7	3.1	27



213	Severe abdominal aortic calcification in older men is negatively associated with DKK1 serum levels: the STRAMBO study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 617-24	5.6	25
212	The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, 727-35	6.5	29
211	Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. <i>Bone</i> , <b>2014</b> , 67, 175-80	4.7	15
210	Ebf factors and MyoD cooperate to regulate muscle relaxation via Atp2a1. <i>Nature Communications</i> , <b>2014</b> , 5, 3793	17.4	26
209	Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2014</b> , 140, 1671-80	4.9	26
208	Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. <i>Breast Cancer Research</i> , <b>2014</b> , 16, R20	8.3	28
207	Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture. <i>Bone</i> , <b>2014</b> , 64, 281-7	4.7	23
206	Chiral spin liquid and emergent anyons in a Kagome lattice Mott insulator. <i>Nature Communications</i> , <b>2014</b> , 5, 5137	17.4	141
205	Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. <i>Bone</i> , <b>2014</b> , 58, 48-54	4.7	118
204	Dickkopf-1 as a mediator and novel target in malignant bone disease. <i>Cancer Letters</i> , <b>2014</b> , 346, 172-7	9.9	31
203	Endocrine aspects of bone metastases. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2014</b> , 2, 500-12	18.1	65
202	Zoledronic acid and atorvastatin inhibit $\alpha$ <sub>v</sub> $\beta$ <sub>3</sub> -mediated adhesion of breast cancer cells. <i>Journal of Bone Oncology</i> , <b>2014</b> , 3, 10-7	4.5	13
201	Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2014</b> , 2, 830-42	18.1	73
200	Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. <i>Molecular Cancer</i> , <b>2014</b> , 13, 265	42.1	12
199	Are there still east-to-west differences in the incidence of hip fractures in Germany?. <i>Archives of Osteoporosis</i> , <b>2014</b> , 9, 195	2.9	5
198	High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. <i>BMC Cancer</i> , <b>2014</b> , 14, 649	4.8	44
197	Artificial extracellular matrices with oversulfated glycosaminoglycan derivatives promote the differentiation of osteoblast-precursor cells and premature osteoblasts. <i>BioMed Research International</i> , <b>2014</b> , 2014, 938368	3	32
196	Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. <i>Nature Communications</i> , <b>2014</b> , 5, 5215	17.4	127

195	Sulfated glycosaminoglycans support osteoblast functions and concurrently suppress osteoclasts. <i>Journal of Cellular Biochemistry</i> , <b>2014</b> , 115, 1101-11	4.7	49
194	Macroglossia as the only presenting feature of amyloidosis due to MGUS. <i>European Journal of Haematology</i> , <b>2014</b> , 92, 88-9	3.8	4
193	Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus. <i>Clinical Endocrinology</i> , <b>2014</b> , 80, 649-55	3.4	34
192	Effects of parathyroid hormone on bone mass, bone strength, and bone regeneration in male rats with type 2 diabetes mellitus. <i>Endocrinology</i> , <b>2014</b> , 155, 1197-206	4.8	53
191	Glycosaminoglycans and their sulfate derivatives differentially regulate the viability and gene expression of osteocyte-like cell lines. <i>Journal of Bioactive and Compatible Polymers</i> , <b>2014</b> , 29, 474-485	2	8
190	Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin. <i>Journal of Bone Oncology</i> , <b>2014</b> , 3, 18-24	4.5	5
189	The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. <i>Osteoporosis International</i> , <b>2014</b> , 25, 339-47	5.3	17
188	Osteoprotegerin: a new biomarker for impaired bone metabolism in complex regional pain syndrome?. <i>Pain</i> , <b>2014</b> , 155, 889-895	8	25
187	Interaktion von Tumorzellen und Knochen bei osteolytischen/osteosklerotischen Metastasen, Circulus vitiosus der Knochenmetastasierung <b>2014</b> , 13-21		
186	Monocytic expression of osteoclast-associated receptor (OSCAR) is induced in atherosclerotic mice and regulated by oxidized low-density lipoprotein in vitro. <i>Biochemical and Biophysical Research Communications</i> , <b>2013</b> , 437, 314-8	3.4	9
185	Monitoring of the first stages of bone healing with microdialysis. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , <b>2013</b> , 84, 76-81	4.3	12
184	Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I. <i>American Journal of Medicine</i> , <b>2013</b> , 126, 174-80	2.4	26
183	The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF- $\kappa$ B ligand/osteoprotegerin complex formation. <i>Biomaterials</i> , <b>2013</b> , 34, 7653-61	15.6	27
182	Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy. <i>Mayo Clinic Proceedings</i> , <b>2013</b> , 88, 418-9	6.4	29
181	Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED)--a prospective multicenter study. <i>Epilepsy Research</i> , <b>2013</b> , 106, 417-22	3	15
180	Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 627-38	6.3	84
179	Regulation of VEGF by mevalonate pathway inhibition in breast cancer. <i>Journal of Bone Oncology</i> , <b>2013</b> , 2, 110-5	4.5	8
178	Effects of the selective glucocorticoid receptor modulator compound A on bone metabolism and inflammation in male mice with collagen-induced arthritis. <i>Endocrinology</i> , <b>2013</b> , 154, 3719-28	4.8	34

177	Skeletal and soft tissue involvement in Mazabraud syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, E1381-2	5.6	1
176	Deconstructing vitamin D deficiency. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 193fs27	17.5	0
175	NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 4731-8	15.9	108
174	Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. <i>Journal of Bone and Mineral Research</i> , <b>2013</b> , 28, 1760-70	6.3	43
173	Mesenchymal stromal cells from patients with myelodysplastic syndrome display distinct functional alterations that are modulated by lenalidomide. <i>Haematologica</i> , <b>2013</b> , 98, 1677-85	6.6	54
172	Impact Of The Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib In Young Rats On The Vertebral Body. <i>Blood</i> , <b>2013</b> , 122, 1472-1472	2.2	2
171	The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , <b>2012</b> , 36, 525-36	2.7	47
170	Novel therapies in benign and malignant bone diseases. <i>Pharmacology &amp; Therapeutics</i> , <b>2012</b> , 134, 338-44	13.9	22
169	Selective glucocorticoid receptor modulation maintains bone mineral density in mice. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 2242-50	6.3	66
168	A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. <i>Osteoporosis International</i> , <b>2012</b> , 23, 2257-76	5.3	233
167	Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions. <i>Clinical Biochemistry</i> , <b>2012</b> , 45, 237-42	3.5	12
166	Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. <i>Experimental Hematology</i> , <b>2012</b> , 40, 867-76	3.1	22
165	Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells. <i>Experimental Hematology</i> , <b>2012</b> , 40, 934-44	3.1	15
164	Quantitative proteomics reveals novel functions of osteoclast-associated receptor in STAT signaling and cell adhesion in human endothelial cells. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2012</b> , 53, 829-37	5.8	15
163	Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, E575-83	5.6	63
162	Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells. <i>Bone</i> , <b>2012</b> , 50, 723-32	4.7	17
161	Regulation of bone mass and osteoclast function depend on the F-actin modulator SWAP-70. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 2085-96	6.3	27
160	The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways. <i>Biomaterials</i> , <b>2012</b> , 33, 8418-29	15.6	59

159	An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. <i>Archives of Osteoporosis</i> , <b>2012</b> , 7, 25-30	2.9	29
158	Denosumab for post-transplantation hypercalcemia in osteopetrosis. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 1766-7	59.2	39
157	Calcification inhibitors in vascular calciphylaxis associated with normal renal function. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 1241-3	7	4
156	WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 575-85	6.3	83
155	Bone, sweet bone--osteoporotic fractures in diabetes mellitus. <i>Nature Reviews Endocrinology</i> , <b>2012</b> , 8, 297-305	15.2	231
154	The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. <i>Nature Immunology</i> , <b>2012</b> , 13, 465-73	19.1	290
153	Regenerative potential of glycosaminoglycans for skin and bone. <i>Journal of Molecular Medicine</i> , <b>2012</b> , 90, 625-35	5.5	146
152	Skeletal and extraskeletal actions of denosumab. <i>Endocrine</i> , <b>2012</b> , 42, 52-62	4	33
151	The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience. <i>Hormone and Metabolic Research</i> , <b>2012</b> , 44, 215-20	3.1	22
150	Serum myostatin levels are negatively associated with abdominal aortic calcification in older men: the STRAMBO study. <i>European Journal of Endocrinology</i> , <b>2012</b> , 167, 873-80	6.5	15
149	Pulmonary metastases due to a giant-cell tumor of bone. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 3408-9	5.6	2
148	Combined use of 68Ga-DOTATATE and 18F-FDG PET/CT to localize a bronchial carcinoid associated with ectopic ACTH syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 2207-8	5.6	13
147	Endocrine and clinical correlates of myostatin serum concentration in men--the STRAMBO study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 3700-8	5.6	38
146	Pheochromocytoma - update on disease management. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2012</b> , 3, 11-26	4.5	52
145	Osteometabolic and osteogenetic pattern of Turkish immigrants in Germany. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2012</b> , 120, 517-23	2.3	10
144	Basics of Bone Biology <b>2012</b> , 1-26		4
143	RANKL Inhibition: Clinical Data <b>2012</b> , 217-240		
142	Skeletal Effects of the Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib in Young Rats. <i>Blood</i> , <b>2012</b> , 120, 4429-4429	2.2	

141	Optimizing management of myelodysplastic syndromes post-allogeneic transplantation. <i>Expert Review of Hematology</i> , <b>2011</b> , 4, 669-80	2.8	2
140	miR-125b regulates calcification of vascular smooth muscle cells. <i>American Journal of Pathology</i> , <b>2011</b> , 179, 1594-600	5.8	143
139	The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. <i>Cancer Letters</i> , <b>2011</b> , 312, 101-8	9.9	13
138	Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. <i>Biochemical and Biophysical Research Communications</i> , <b>2011</b> , 407, 103-7	3.4	23
137	Osteoporosis: now and the future. <i>Lancet, The</i> , <b>2011</b> , 377, 1276-87	40	1443
136	Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. <i>Haematologica</i> , <b>2011</b> , 96, 1580-8	6.6	17
135	Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. <i>Transplant International</i> , <b>2011</b> , 24, 867-79	3	33
134	The osteoclast-associated receptor (OSCAR) is a novel receptor regulated by oxidized low-density lipoprotein in human endothelial cells. <i>Endocrinology</i> , <b>2011</b> , 152, 4915-26	4.8	31
133	Nuclear factor of activated T cells mediates oxidised LDL-induced calcification of vascular smooth muscle cells. <i>Diabetologia</i> , <b>2011</b> , 54, 2690-701	10.3	33
132	Is there still a place for adrenal venous sampling in the diagnostic localization of pheochromocytoma?. <i>Endocrine</i> , <b>2011</b> , 40, 75-9	4	6
131	Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. <i>Journal of Cellular Biochemistry</i> , <b>2011</b> , 112, 1593-600	4.7	39
130	Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 411-20	5.5	225
129	Dissociation of osteogenic and immunological effects by the selective glucocorticoid receptor agonist, compound A, in human bone marrow stromal cells. <i>Endocrinology</i> , <b>2011</b> , 152, 103-12	4.8	39
128	Seizures associated with zoledronic acid for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 1955-9	5.6	20
127	An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. <i>FASEB Journal</i> , <b>2011</b> , 25, 1323-32	0.9	62
126	Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 2216-26	5.6	20
125	Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 28761-28771	5.4	21
124	Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2011</b> , 301, E1220-8	6	99

123	The role of osteoclast-associated receptor in osteoimmunology. <i>Journal of Immunology</i> , <b>2011</b> , 186, 13-8	5.3	62
122	Denosumab for bone diseases: translating bone biology into targeted therapy. <i>European Journal of Endocrinology</i> , <b>2011</b> , 165, 833-40	6.5	31
121	Diabetes Mellitus and Osteoporosis <b>2011</b> , 103-108		
120	Approach to the patient with secondary osteoporosis. <i>European Journal of Endocrinology</i> , <b>2010</b> , 162, 1009-20	6.5	69
119	Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. <i>Cancer Letters</i> , <b>2010</b> , 287, 109-16	9.9	51
118	A novel resorption assay for osteoclast functionality based on an osteoblast-derived native extracellular matrix. <i>Journal of Cellular Biochemistry</i> , <b>2010</b> , 109, 1025-32	4.7	33
117	Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. <i>European Journal of Endocrinology</i> , <b>2009</b> , 161, 27-35	6.5	55
116	Long-term cyclic strain downregulates endothelial Nox4. <i>Antioxidants and Redox Signaling</i> , <b>2009</b> , 11, 2385-97	8.4	32
115	Minireview: live and let die: molecular effects of glucocorticoids on bone cells. <i>Molecular Endocrinology</i> , <b>2009</b> , 23, 1525-31		60
114	The German ACROSTUDY: past and present. <i>European Journal of Endocrinology</i> , <b>2009</b> , 161 Suppl 1, S3-S16	5.5	53
113	Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. <i>Journal of Cellular Biochemistry</i> , <b>2009</b> , 108, 106-16	4.7	33
112	Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 1427-37		104
111	Medial arterial calcification in diabetes and its relationship to neuropathy. <i>Diabetologia</i> , <b>2009</b> , 52, 2478-88	8.3	75
110	Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. <i>Journal of Bone and Mineral Research</i> , <b>2009</b> , 24, 153-61	6.3	399
109	Inhibition of lamin A/C attenuates osteoblast differentiation and enhances RANKL-dependent osteoclastogenesis. <i>Journal of Bone and Mineral Research</i> , <b>2009</b> , 24, 78-86	6.3	50
108	Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. <i>Bone</i> , <b>2009</b> , 45, 677-81	4.7	35
107	Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. <i>American Journal of Pathology</i> , <b>2009</b> , 175, 473-8	5.8	121
106	Multimodal therapy for vertebral involvement of systemic mastocytosis. <i>Spine</i> , <b>2009</b> , 34, E626-8	3.3	6



105	Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial <b>2009</b> , 24, 153		4
104	Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. <i>Journal of Bone and Mineral Research</i> , <b>2008</b> , 23, 750-8	6.3	57
103	17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 368, 736-41	3.4	23
102	Exploring the biology of vascular calcification in chronic kidney disease: what's circulating?. <i>Kidney International</i> , <b>2008</b> , 73, 384-90	9.9	102
101	The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. <i>Nephrology Dialysis Transplantation</i> , <b>2008</b> , 23, 3263-71	4.3	138
100	Osteoprotegerin expression in dendritic cells increases with maturation and is NF-kappaB-dependent. <i>Journal of Cellular Biochemistry</i> , <b>2007</b> , 100, 1430-9	4.7	33
99	Osteoporosis in patients with diabetes mellitus. <i>Journal of Bone and Mineral Research</i> , <b>2007</b> , 22, 1317-28	6.3	344
98	Vascular calcification and osteoporosis--from clinical observation towards molecular understanding. <i>Osteoporosis International</i> , <b>2007</b> , 18, 251-9	5.3	180
97	Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. <i>Diabetologia</i> , <b>2007</b> , 50, 1243-7	10.3	33
96	Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. <i>Endocrine</i> , <b>2007</b> , 31, 105-13	4	26
95	Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. <i>Molecular and Cellular Endocrinology</i> , <b>2007</b> , 264, 74-81	4.4	40
94	Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. <i>Journal of Cellular Biochemistry</i> , <b>2006</b> , 98, 954-65	4.7	11
93	Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. <i>Rheumatology</i> , <b>2006</b> , 45, 1218-22	3.9	44
92	Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. <i>Atherosclerosis</i> , <b>2006</b> , 184, 446-7	3.1	60
91	Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 708-714	7	21
90	Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells. <i>Endocrine</i> , <b>2006</b> , 30, 129-38		13
89	Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. <i>Osteoporosis International</i> , <b>2006</b> , 17, 693-703	5.3	65
88	Bedeutung von RANK-Ligand und Osteoprotegerin fñ den Knochenstoffwechsel <b>2006</b> , 479-509		



87	Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. <i>Thrombosis and Haemostasis</i> , <b>2006</b> , 95, 708-14	7	13
86	Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 338, 687-93	3-4	63
85	TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 338, 1745-50	3-4	16
84	Gorham-Stout disease--stabilization during bisphosphonate treatment. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 350-3	6-3	81
83	Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 2036-43	6-3	28
82	Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. <i>Journal of Cellular Biochemistry</i> , <b>2005</b> , 96, 1244-53	4-7	57
81	Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification. <i>Thrombosis and Haemostasis</i> , <b>2005</b> , 94, 1335-7	7	11
80	Osteoprotegerin gene polymorphisms in men with coronary artery disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 3764-8	5-6	80
79	Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 6139-45	5-6	54
78	Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mückeberg's sclerosis and atherosclerosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 4104-12	5-6	166
77	Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2004</b> , 130, 469-74	4-9	28
76	Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. <i>Acta Neuropathologica</i> , <b>2004</b> , 107, 575-7, author reply 578	14-3	11
75	Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. <i>Clinical Endocrinology</i> , <b>2004</b> , 60, 214-9	3-4	46
74	Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. <i>Calcified Tissue International</i> , <b>2004</b> , 74, 103-6	3-9	83
73	Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. <i>JAMA - Journal of the American Medical Association</i> , <b>2004</b> , 292, 490-5	27-4	678
72	Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. <i>Blood</i> , <b>2004</b> , 103, 3480-9	2-2	94
71	Increased osteoprotegerin serum levels in men with coronary artery disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 1024-8	5-6	274
70	Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 4206-13	5-6	81

69	Skeletal effects of cyclosporin A are gender related in rats. <i>Endocrinology</i> , <b>2003</b> , 144, 40-9	4.8	22
68	Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2003</b> , 15, 1165-70	2.2	38
67	Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. <i>American Journal of Hematology</i> , <b>2003</b> , 72, 34-7	7.1	11
66	Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2003</b> , 17, 807-16	6.1	54
65	Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. <i>Circulation</i> , <b>2003</b> , 107, e76; author reply e76	16.7	43
64	RANK ligand and osteoprotegerin in myeloma bone disease. <i>Blood</i> , <b>2003</b> , 101, 2094-8	2.2	211
63	Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 1436-40	12.9	113
62	Cytokine inhibition: a new therapeutic avenue for skeletal diseases. <i>Drug Discovery Today</i> , <b>2002</b> , 7, 289	8.8	
61	Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. <i>Journal of Cellular Biochemistry</i> , <b>2002</b> , 84, 725-35	4.7	70
60	Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. <i>Journal of Cellular Biochemistry</i> , <b>2002</b> , 86, 642-50	4.7	25
59	In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2002</b> , 110, 386-92	2.3	31
58	Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 4078-9	5.6	35
57	Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. <i>European Journal of Endocrinology</i> , <b>2002</b> , 147, 269-73	6.5	54
56	RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2002</b> , 22, 549-53	9.4	315
55	Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. <i>Biochemical and Biophysical Research Communications</i> , <b>2002</b> , 291, 680-6	3.4	243
54	VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. <i>Surgery</i> , <b>2002</b> , 132, 1056-63; discussion 1063	3.6	44
53	Serum measurement of osteoprotegerin--clinical relevance and potential applications. <i>European Journal of Endocrinology</i> , <b>2001</b> , 145, 681-3	6.5	32
52	Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. <i>Journal of Molecular Medicine</i> , <b>2001</b> , 79, 243-53	5.5	424

51	Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. <i>Cancer</i> , <b>2001</b> , 92, 460-70	6.4	144
50	The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 44, 253-9		83
49	Bone and mineral metabolism in human immunodeficiency virus infection. <i>Journal of Bone and Mineral Research</i> , <b>2001</b> , 16, 2-9	6.3	30
48	Identical twins with hypercalcaemia due to Lowe's syndrome. <i>Rheumatology</i> , <b>2001</b> , 40, 107-8	3.9	2
47	Leptin reduces ovariectomy-induced bone loss in rats. <i>Endocrinology</i> , <b>2001</b> , 142, 3546-53	4.8	236
46	Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2001</b> , 280, 334-9	3.4	180
45	Osteoprotegerin: a link between osteoporosis and arterial calcification?. <i>Lancet, The</i> , <b>2001</b> , 358, 257-9	4.0	100
44	Osteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 3162-3165	5.6	146
43	The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. <i>Journal of Bone and Mineral Research</i> , <b>2000</b> , 15, 2-12	6.3	861
42	The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. <i>Endocrinology</i> , <b>2000</b> , 141, 4768-76	4.8	230
41	Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 2355-63	5.6	129
40	The Role of Receptor Activator of Nuclear Factor- $\kappa$ B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 2355-2363	5.6	109
39	Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. <i>Endocrinology</i> , <b>1999</b> , 140, 5579-86	4.8	75
38	Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. <i>Endocrinology</i> , <b>1999</b> , 140, 4367-70	4.8	529
37	Gorham-Stout disease (phantom bone) of the shoulder girdle. <i>Rheumatology</i> , <b>1999</b> , 38, 904-5	3.9	11
36	Androgen effects on bone metabolism: recent progress and controversies. <i>European Journal of Endocrinology</i> , <b>1999</b> , 140, 271-86	6.5	96
35	Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. <i>Endocrinology</i> , <b>1999</b> , 140, 4382-9	4.8	582
34	The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. <i>Journal of Bone and Mineral Research</i> , <b>1999</b> , 14, 1330-7	6.3	56

33	Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. <i>Bone</i> , <b>1999</b> , 25, 255-9	4.7	518
32	Osteopetrosis in cathepsin K-deficient mice. <i>European Journal of Endocrinology</i> , <b>1999</b> , 140, 376-7	6.5	14
31	Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. <i>European Journal of Endocrinology</i> , <b>1999</b> , 141, 195-210	6.5	87
30	Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. <i>Journal of Cellular Biochemistry</i> , <b>1998</b> , 71, 96-108	4.7	42
29	Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. <i>Biochemical and Biophysical Research Communications</i> , <b>1998</b> , 250, 776-81	3.4	261
28	Vitamin D receptor knock-out mice: the expectational and the exceptional. <i>European Journal of Endocrinology</i> , <b>1998</b> , 138, 372-3	6.5	3
27	Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. <i>European Journal of Endocrinology</i> , <b>1998</b> , 139, 152-4	6.5	53
26	Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen. <i>Journal of Clinical Investigation</i> , <b>1998</b> , 101, 413-22	15.9	74
25	Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line <b>1998</b> , 71, 96		1
24	Hyperactive channels and inherited hypertension: Liddle's syndrome--an epithelial sodium channelopathy. <i>European Journal of Endocrinology</i> , <b>1997</b> , 136, 588-9	6.5	1
23	Graves Disease Associated With Autoimmune Thrombocytopenic Purpura. <i>Archives of Internal Medicine</i> , <b>1997</b> , 157, 1033		20
22	Coagulation disorders in thyroid diseases. <i>European Journal of Endocrinology</i> , <b>1997</b> , 136, 1-7	6.5	71
21	Less can be more--at least in mice: osteocalcin deficiency associated with increased bone formation. <i>European Journal of Endocrinology</i> , <b>1997</b> , 136, 586-7	6.5	1
20	Multiple endocrine neoplasia type 2: recent progress in diagnosis and management. <i>European Journal of Endocrinology</i> , <b>1997</b> , 137, 572-8	6.5	18
19	Osteoprotegerin: a novel local player in bone metabolism. <i>European Journal of Endocrinology</i> , <b>1997</b> , 137, 345-6	6.5	7
18	Dermatitis herpetiformis cured by hormone replacement for panhypopituitarism. <i>Endocrine Journal</i> , <b>1997</b> , 44, 437-40	2.9	6
17	Mediastinal Parathyroid Tumor: Giant Adenoma or Carcinoma?. <i>Endocrine Pathology</i> , <b>1997</b> , 8, 161-166	4.2	5
16	Development and characterization of a conditionally immortalized human osteoblastic cell line stably transfected with the human androgen receptor gene. <i>Journal of Cellular Biochemistry</i> , <b>1997</b> , 66, 542-51	4.7	16

15	Soluble Interleukin-1 Receptor Antagonist Serum Levels in Smokers and Nonsmokers with GravesR Ophthalmopathy Undergoing Orbital Radiotherapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 2244-2247	5.6	41
14	Graves disease associated with autoimmune thrombocytopenic purpura. <i>Archives of Internal Medicine</i> , <b>1997</b> , 157, 1033-1036		9
13	Intercellular chatter: osteoblasts, osteoclasts and interleukin 6. <i>European Journal of Endocrinology</i> , <b>1996</b> , 134, 425-6	6.5	16
12	Of bone and genes: vitamin D receptor polymorphism and primary hyperparathyroidism. <i>European Journal of Endocrinology</i> , <b>1996</b> , 134, 685-6	6.5	
11	Antibodies targeting the calcium sensing receptor: acquired hypoparathyroidism--an autoimmune disease at last?. <i>European Journal of Endocrinology</i> , <b>1996</b> , 135, 172-3	6.5	0
10	Endocrinology meets immunology: T lymphocytes as novel targets for melatonin. <i>European Journal of Endocrinology</i> , <b>1996</b> , 134, 424-5	6.5	12
9	Updating the metalloprotease nomenclature: bone morphogenetic protein 1 identified as procollagen C proteinase. <i>European Journal of Endocrinology</i> , <b>1996</b> , 135, 35-6	6.5	4
8	How iodide gets access to thyrocytes: molecular details on the thyroid iodide transporter. <i>European Journal of Endocrinology</i> , <b>1996</b> , 135, 34-5	6.5	
7	Endocrine implications of human immunodeficiency virus infection. <i>Medicine (United States)</i> , <b>1996</b> , 75, 262-78	1.8	43
6	Human immunodeficiency virus infection and the thyroid gland. <i>European Journal of Endocrinology</i> , <b>1996</b> , 134, NP-674	6.5	3
5	Environmental endocrinology: hidden, but potent ways of activating the estrogen receptor. <i>European Journal of Endocrinology</i> , <b>1996</b> , 135, 653-4	6.5	
4	Taking the message to the nucleus: MAD protein as a mediator of bone morphogenetic protein signaling. <i>European Journal of Endocrinology</i> , <b>1996</b> , 135, 654-5	6.5	2
3	Greetings from below the aortic arch! The paradigm of cardiac paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1996</b> , 81, 891-895	5.6	6
2	Insulin-like growth factor I messenger ribonucleic acid expression in porcine thyroid follicles is regulated by thyrotropin and iodine. <i>European Journal of Endocrinology</i> , <b>1995</b> , 132, 605-10	6.5	30
1	Viscous hearing loss. <i>Lancet, The</i> , <b>1995</b> , 345, 1243	40	0